NCT06334614

Brief Summary

The broad goal of this clinical trial is to demonstrate whether a one-month rehabilitative training with our medical device, iReach, can promote the recovery of spatial and sensorimotor abilities and the cortical reorganization process in children with visual impairment between 3 and 36 months of age.

Trial Health

35
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
55

participants targeted

Target at P25-P50 for not_applicable

Timeline
Completed

Started Dec 2024

Status
not yet recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

March 20, 2024

Completed
8 days until next milestone

First Posted

Study publicly available on registry

March 28, 2024

Completed
9 months until next milestone

Study Start

First participant enrolled

December 8, 2024

Completed
5 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

May 8, 2025

Completed
7 months until next milestone

Study Completion

Last participant's last visit for all outcomes

December 8, 2025

Completed
Last Updated

March 28, 2024

Status Verified

March 1, 2024

Enrollment Period

5 months

First QC Date

March 20, 2024

Last Update Submit

March 27, 2024

Conditions

Keywords

blindnessinfantsrehabilitationmultisensory motor trainingmedical device

Outcome Measures

Primary Outcomes (1)

  • Incidence of Device Adverse Events

    Verification of the absence of device adverse events in the use of the medical device (MD);

    Month 1 - Month 12, the entire duration of the clinical trial

Secondary Outcomes (4)

  • Change in motor skills after training with iReach medical device

    Month 3 - Month 12

  • Perceptual responses to multisensory stimuli

    Month 1 - Month 12

  • Change in motor abilities following the rehabilitation with the iReach medical device

    Month 1 - Month 12

  • Variation in the power of the cortical activity following the rehabilitation with the iReach medical device

    Month 1 - Month 12

Study Arms (2)

iReach Device group

EXPERIMENTAL

The iReach Device group will undergo the clinical trial with the device in addition to the normal clinical activity

Device: iReach

Normal clinical activity group

NO INTERVENTION

The Normal clinical activity group will continue their normal clinical activity

Interventions

iReachDEVICE

The iReach Device group will take part in playful multisensory motor and spatial activities for one month both at the clinic and at home with the medical device iReach.

iReach Device group

Eligibility Criteria

Age3 Months - 36 Months
Sexall
Healthy VolunteersYes
Age GroupsChild (0-17)

You may qualify if:

  • Obtaining Informed Consent;
  • Age between 3 and 36 months;
  • Normal vision or visual acuity between 0 and 4.7 cy/deg, assessed using the Teller Acuity Cards;
  • Absence of concurrent therapies during the experimentation;
  • Adequate cognitive ability for their age, assessed using the Reynell-Zinkin, Bayley III, and/or Griffiths scales;

You may not qualify if:

  • Children with neurological disorders or cognitive delays (assessed using the Reynell-Zinkin, Bayley III, and/or Griffiths scales);
  • Children affected by other sensory disabilities in addition to visual impairment (e.g., deafness) or with motor disorders;
  • Premature infants with early gestational age (\< 32 weeks);
  • Children with diseases affecting the central nervous system or who have experienced epileptic seizures and/or convulsions in the six months before the start of the experimentation;
  • Children with tactile hypersensitivity who are taking neuroactive drugs and substances or have taken them in the six months before the start of the experimentation;
  • Children with auditory and/or peripheral motor disabilities;
  • Children whose parents or legal guardians have not provided informed consent;

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Related Publications (7)

  • Campus C, Signorini S, Vitali H, De Giorgis V, Papalia G, Morelli F, Gori M. Sensitive period for the plasticity of alpha activity in humans. Dev Cogn Neurosci. 2021 Jun;49:100965. doi: 10.1016/j.dcn.2021.100965. Epub 2021 May 21.

    PMID: 34051686BACKGROUND
  • Cappagli G, Cocchi E, Gori M. Auditory and proprioceptive spatial impairments in blind children and adults. Dev Sci. 2017 May;20(3). doi: 10.1111/desc.12374. Epub 2015 Nov 27.

    PMID: 26613827BACKGROUND
  • Cappagli G, Finocchietti S, Cocchi E, Giammari G, Zumiani R, Cuppone AV, Baud-Bovy G, Gori M. Audio motor training improves mobility and spatial cognition in visually impaired children. Sci Rep. 2019 Mar 1;9(1):3303. doi: 10.1038/s41598-019-39981-x.

    PMID: 30824830BACKGROUND
  • Finocchietti S, Cappagli G, Ben Porquis L, Baud-Bovy G, Cocchi E, Gori M. Evaluation of the Audio Bracelet for Blind Interaction for improving mobility and spatial cognition in early blind children - A pilot study. Annu Int Conf IEEE Eng Med Biol Soc. 2015 Aug;2015:7998-8001. doi: 10.1109/EMBC.2015.7320248.

    PMID: 26738148BACKGROUND
  • Gori M, Campus C, Signorini S, Rivara E, Bremner AJ. Multisensory spatial perception in visually impaired infants. Curr Biol. 2021 Nov 22;31(22):5093-5101.e5. doi: 10.1016/j.cub.2021.09.011. Epub 2021 Sep 22.

    PMID: 34555348BACKGROUND
  • Setti W, Cuturi LF, Engel I, Picinali L, Gori M. The influence of early visual deprivation on audio-spatial working memory. Neuropsychology. 2022 Jan;36(1):55-63. doi: 10.1037/neu0000776. Epub 2021 Oct 14.

    PMID: 34647755BACKGROUND
  • Vercillo T, Gori M. Attention to sound improves auditory reliability in audio-tactile spatial optimal integration. Front Integr Neurosci. 2015 May 7;9:34. doi: 10.3389/fnint.2015.00034. eCollection 2015.

    PMID: 25999825BACKGROUND

Related Links

MeSH Terms

Conditions

BlindnessVision Disorders

Condition Hierarchy (Ancestors)

Sensation DisordersNeurologic ManifestationsNervous System DiseasesEye DiseasesSigns and SymptomsPathological Conditions, Signs and Symptoms

Central Study Contacts

Walter Setti, PhD

CONTACT

Monica Gori, PhD

CONTACT

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
SINGLE
Who Masked
PARTICIPANT
Masking Details
Participant masking because the clinical trial involves infants
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

March 20, 2024

First Posted

March 28, 2024

Study Start

December 8, 2024

Primary Completion

May 8, 2025

Study Completion

December 8, 2025

Last Updated

March 28, 2024

Record last verified: 2024-03

Data Sharing

IPD Sharing
Will share